Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Bispecific T-Cell Engagers Market Insights Report (2026-2030) Featuring Strategic Analysis of Pfizer, Johnson & Johnson, Roche, AbbVie, Sanofi and Other Key Players

globenewswire.com
PFE Pfizer is listed as a key player in the growing bispecific T-cell engagers market, indicating its involvement in a high-growth sector. JNJ Johnson & Johnson is identified as a leading player in the bispecific T-cell engagers market, suggesting participation in a significant and expanding therapeutic area. AMGN Amgen is highlighted for its introduction of IMDELLTRA, a novel FDA-approved therapy for small cell lung cancer, demonstrating innovation and market leadership in bispecific T-cell engagers. ABBV AbbVie is mentioned as a key player in the bispecific T-cell engagers market, indicating its presence in a sector with strong projected growth. SNY Sanofi is listed as a leading company in the bispecific T-cell engagers market, suggesting its involvement in a rapidly expanding and important therapeutic area. MRK Merck & Co. is noted for its acquisition of Harpoon Therapeutics Inc., reflecting strategic investment and momentum in the oncology and bispecific T-cell engagers space. REGN Regeneron Pharmaceuticals is identified as a leading player in the bispecific T-cell engagers market, indicating its participation in a growing and significant therapeutic area.

Bispecific T-Cell Engagers Market Insights Report (2026-2030) Featuring Strategic Analysis of Pfizer, Johnson & Johnson, Roche, AbbVie, Sanofi and Other Key Players Dublin, March 27, 2026 (GLOBE NEWSWIRE) -- The "Bispecific T-Cell Engagers Market Report 2026" has been added to ResearchAndMarkets.com's offering.

The bispecific T-cell engagers market is witnessing remarkable growth with projections showcasing a rise from $1.6 billion in 2025 to $1.94 billion by 2026, marking a CAGR of 21.3%. This trend is attributed to factors like limited efficacy of conventional cancer therapies, rising incidence of hematologic malignancies, breakthroughs in immune-oncology, and increased oncology research investments. Forecasts anticipate the market could reach $4.18 billion by 2030, sustaining a 21.2% CAGR, driven by technological advancements in antibody engineering, higher healthcare investments, and growing strategic partnerships.

Bispecific T-cell engagers are crucial in the fight against cancer, particularly due to the rising global cancer incidence. The mechanism involves binding to both T cells and tumor cells, harnessing the immune system to target cancer more effectively. Reports indicate a significant increase in cancer cases, from 20 million in 2022, expected to surge by 77% to over 35 million by 2050. This alarming rise emphasizes the growing demand for innovative therapies like bispecific T-cell engagers.

Noteworthy corporate strategies are shaping the landscape, with companies focusing on enhancing techniques like cytolytic synapse formation. For instance, Amgen Inc. introduced IMDELLTRA (tarlatamab-dlle) in May 2024, a pioneering therapy approved by the FDA for extensive-stage small cell lung cancer, offering a novel approach in tumor cell targeting. Additionally, acquisitions such as Merck & Co. Inc.'s acquisition of Harpoon Therapeutics Inc. reflect the industry's momentum towards expanded oncology treatments.

Leading players in the market include giants like Pfizer, Johnson & Johnson, Amgen, Sanofi, and Regeneron Pharmaceuticals, among others. Geographically, North America emerged as the largest market in 2025, with Asia-Pacific anticipated to be the fastest growing region moving forward.

Report Scope

This report addresses the largest and fastest-growing areas within the bispecific T-cell engagers market, analyzing its correlation with broader economic and demographic trends. Key influences include technological innovations, changing regulatory frameworks, and consumer preference shifts.

The report provides a detailed breakdown of market characteristics, growth, segmentation, and competitive dynamics. It tracks historical and forecast growth by geography, exploring major innovations and product developments that differentiate market offerings.

Markets Covered:

Main Companies: Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche AG, AbbVie Inc., Sanofi S.A., Amgen Inc., among others.

Geographic Coverage: Major countries include the USA, China, Germany, and Brazil, among others, spanning regions such as Asia-Pacific and North America.

The report includes historic data over the past five years and forecasts for ten years ahead, ensuring a comprehensive understanding of market dynamics. Delivered in Word, PDF, or interactive formats with an Excel dashboard, the data is fully customizable and updated bi-annually, supported by expert consultancy services, providing a robust toolkit for decision-makers in the bispecific T-cell engagers market.

Key Attributes

The companies featured in this Bispecific T-Cell Engagers market report include:

For more information about this report visit https://www.researchandmarkets.com/r/cfsuj8

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Attachment